English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The therapeutic role of interleukin (IL)-1 receptor antagonist, a potent inhibitor of IL-1, was investigated using peripheral blood mononuclear cells from patients with ulcerative colitis and Crohn's disease. Administration of IL-1 receptor antagonist inhibited IL-1 beta-augmented IL-1 alpha and tumor necrosis factor-alpha production by mononuclear cells. Prednisolone caused a decrease in IL-1 receptor antagonist release, whereas sulfasalazine had no modulatory effect. Interestingly, IgG caused an increase in IL-1 receptor antagonist release. In conclusion, IL-1 receptor antagonist and related molecules may have therapeutic value.

Therapeutic Potential of Interleukin-1 Receptor Antagonist in Inflammatory Bowel Disease.